SIGNET RING CELL ADENOCARCINOMA
Clinical trials for SIGNET RING CELL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new SIGNET RING CELL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for SIGNET RING CELL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Matched conditions: SIGNET RING CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo aims to outsmart stubborn colorectal cancer
Disease control OngoingThis phase 2 trial tests whether combining the immunotherapy nivolumab (Opdivo) with the chemotherapy oxaliplatin can help control or shrink metastatic colorectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS)—types that usually don't respond well…
Matched conditions: SIGNET RING CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University Hospital, Akershus • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC